Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1954 • ACR Convergence 2022
Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews
Simon Helfgott¹, Kent Kwas Huston², Jasvinder singh³, Nehad Soloman⁴, Jeremy Broestl⁵, Kimmi Cox⁵, Kelsey Milligan⁵ and Colin Edgerton⁶, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁵Trio Health, Louisville, CO, ⁶Articularis Healthcare, Sullivans Island, SC
Background/Purpose: Clinical and non-clinical forces contribute to real-world treatment effectiveness, yet most studies focus on efficacy in an idealized setting. To identify factors impacting clinical…
Abstract Number: 1971 • ACR Convergence 2022
Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment
Sascha Heckert¹, Sytske Anne Bergstra², Yvonne Goekoop-Ruiterman³, Melek Guler-Yuksel⁴, Willem Lems⁵, Xanthe Matthijssen⁶, Maikel Van Oosterhout⁷, Tom Huizinga⁶ and CF Allaart⁶, ¹Leiden University Medical Centre, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³HagaZiekenhuis, The Hague, Netherlands, ⁴Maasstad ziekenhuis, Rotterdam, Netherlands, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands
Background/Purpose: In Rheumatoid Arthritis (RA), both systemic and local disease activity have been shown to be associated with joint damage progression. Earlier we showed that…
Abstract Number: 1989 • ACR Convergence 2022
Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Nada Alrifai¹, Mohamed Tageldin², Malavikalakshmi Attur², Nicholas Wilson², Rebecca schorr² and Tarun Sharma², ¹Allegheny Health Network, Pittsburgh, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Few RCTs and real-world studies…
Abstract Number: 2005 • ACR Convergence 2022
Comparison of Treatment and Disease Activity in the Early Stage of Onset in Patients with Elderly-onset vs Younger-onset Rheumatoid Arthritis Using Data of National Database of Rheumatic Diseases in Japan (NinJa)
Toshihiro Matsui¹ and Shigeto Tohma², ¹NHO Sagamihara National Hospital, Kanagawa, Japan, ²National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: To clarify the current status and issues concerning treatment in the early stage of onset in patients with elderly-onset rheumatoid arthritis (RA) in Japan.Methods:…
Abstract Number: 2185 • ACR Convergence 2022
Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis
Anne-Renee van der Vuurst de Vries¹, Kathryn Hooper¹, Jonathan Graf², Katie Tuckwell¹ and Joshua Beilke¹, ¹Sonoma Biotherapeutics, South San Francisco, CA, ²Ucsf, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition with persistent unmet medical need despite significant treatment advances. The pathogenesis of RA is initiated…
Abstract Number: 2250 • ACR Convergence 2022
Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Austin Wheeler¹, Yangyuna Yang¹, Joshua Baker², Jill Poole¹, Dana Ascherman³, Gail Kerr⁴, Andreas Reimold⁵, Gary Kunkel⁶, Grant Cannon⁷, Katherine Wysham⁸, Namrata Singh⁹, Deana Lazaro¹⁰, Paul Monach¹¹, S. Louis Bridges, Jr.¹², Ted Mikuls¹³ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Utah, Salt Lake City, UT, ⁷Retired, Salt Lake City, UT, ⁸VA Puget Sound/University of Washington, Seattle, WA, ⁹University of Washington, Bellevue, WA, ¹⁰VA New York Harbor Healthcare system, Short Hills, NJ, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Hospital for Special Surgery, New York, NY, ¹³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA causing substantial morbidity and mortality. Genetic risk variants, such as the MUC5B rs35705950…
Abstract Number: 0061 • ACR Convergence 2022
Rheumatic Diagnostic Code Trajectories for Patients with RA and SLE in a U.S. Rheumatology Registry
thomas Ituarte¹, Jing Li², Julia Kay³, Zara Izadi⁴, Jinoos Yazdany³ and Gabriela Schmajuk⁵, ¹UCSF, San Francisco, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: Diagnostic uncertainty is a common problem faced by rheumatologists. Even among patients under the care of a rheumatologist, patients may have one rheumatic illness…
Abstract Number: 0119 • ACR Convergence 2022
Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions Varies by Geographic Location of Residence
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Steven Katz², Eileen Davidson³, Clare Hildebrandt⁴, Katie Lin¹, Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: Rheumatology services in Canada are largely restricted to urban centres, resulting in significant access difficulties for residents of rural and remote locations. As a…
Abstract Number: 0242 • ACR Convergence 2022
Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging
Lukas Folle¹, Sara Bayat², Arnd Kleyer³, Filippo Fagni², Lorenz Kapsner⁴, Maja Schlereth⁵, Timo Meinderink², Katharina Breininger⁵, Koray Tascilar³, Gerhard Kroenke³, Michael Uder⁶, MIchael Sticherling⁷, Sebastian Bickelhaupt⁴, Georg Schett⁸, Andreas Maier⁹, Frank Roemer¹⁰ and David Simon³, ¹Friedrich-Alexander-Universitaet Erlangen Nürnberg, Erlangen, Germany, ²University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴University Hospital Erlangen; Institute of Radiology, Erlangen, Germany, ⁵Friedrich-Alexander Universität Erlangen-Nürnberg, Artificial Intelligence in Medical Imaging, Erlangen, Germany, ⁶University Hospital Erlangen; Lehrstuhl für Diagnostische Radiologie, Erlangen, Germany, ⁷University Hospital Erlangen; Institute of Dermatology, Erlangen, Germany, ⁸Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Lehrstuhl für Mustererkennung, Erlangen, Germany, ¹⁰Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany
Background/Purpose: To evaluate (i) whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using MRI data based on…
Abstract Number: 0258 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
Sascha Heckert¹, Tjardo Maarseveen², Emiel Marges², Arvind Chopra³, David Vega Morales⁴, Riette Du Toit⁵, Annette van der Helm-van Mil⁶, Tom Huizinga², CF Allaart² and Sytske Anne Bergstra⁷, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Center for Rheumatic Diseases, Pune, Maharashtra, India, ⁴Hospital General de Zona 17, Instituto Mexicano del Seguro Social, Monterrey, Mexico, ⁵Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa, ⁶Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ⁷LUMC, Leiden, Netherlands
Background/Purpose: Interstitial lung disease (ILD) is a spectrum of inflammatory and fibrotic lung diseases, and can be associated with RA (RA-ILD). The reported prevalence in…
Abstract Number: 0275 • ACR Convergence 2022
Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials
Maya Buch¹, Gerd Burmester², Xavier Mariette³, Christina Charles-Schoeman⁴, Vijay Rajendran⁵, Pieter-Jan Stiers⁶, Agustin Cerani⁶, Paul Van Hoek⁶, Katrien Van Beneden⁶, Yoshiya Tanaka⁷, Hendrik Schulze-Koops⁸, Rene Westhovens⁹ and Ennio Giulio Favalli¹⁰, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Charité University Medicine Berlin, Berlin, Germany, ³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁴Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ⁵Galapagos NV, Gent, Belgium, ⁶Galapagos NV, Mechelen, Belgium, ⁷University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁸Ludwig-Maximilians-University Munich, Munich, Germany, ⁹University Hospitals Leuven, Leuven, Belgium, ¹⁰University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy
Background/Purpose: The safety profile of filgotinib (FIL), a second-generation oral Janus kinase (JAK) 1 preferential inhibitor approved in Europe, Japan, and the UK for treatment…
Abstract Number: 0292 • ACR Convergence 2022
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Andrea Rubbert-Roth¹, Adriana Kakehasi², Tsutomu Takeuchi³, Marc Schmalzing⁴, Hannah Palac⁵, Jianzhong Liu⁵, Samuel Anyanwu⁵, Ralph Lippe⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³Keio University and Saitama Medical University, Tokyo, Japan, ⁴University Hospital Wuerzburg, Wuerzburg, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc, Wiesbaden, Germany, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…
Abstract Number: 0310 • ACR Convergence 2022
Higher Baseline Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis
TING WANG, Natalia V. Giltiay, Christian Lood and Bobby Kwanghoon Han, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Activation of T cells plays a key role in the pathogenesis of rheumatoid arthritis (RA), which is characterized by inflammation of the synovial tissue…
Abstract Number: 0532 • ACR Convergence 2022
Women with Early Rheumatoid Arthritis Less Likely to Achieve Rapid and Sustainable Remission: Results from the Canadian Early Arthritis Cohort Study
orit schieir¹, Susan Bartlett², Marie-France Valois¹, Glen Hazlewood³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, diane tin⁹, Carter Thorne¹⁰, Vivian Bykerk¹¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹McGill University, Montréal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Centre of Arthritis Excellence (CArE), Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²The Canadian Early Arthritis Cohort (CATCH), Bowmanville, ON, Canada
Background/Purpose: Historical and established RA cohorts have reported sex disparities in remission outcomes favoring male patients. The objective of the present study was to compare…
Abstract Number: 0590 • ACR Convergence 2022
Molecular Profiling of Normal Human Synovium Reveals Striking Impact of Adipocytes and Homeostatic Cortisol Signaling
Heather Faust¹, Tan-Yun Cheng¹, Ilya Korsunsky¹, Gerald FM Watts¹, David Moody¹ and Michael Brenner², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The synovium encapsulates joints and contains fibroblasts which proliferate, become invasive, and drive disease progression in rheumatoid arthritis (RA) and osteoarthritis (OA). There is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].